Pakistan released the clinical research results of traditional Chinese medicine in the treatment of new crown pneumonia

According to Reuters reported on the 17th, Pakistan's health authorities released the results of a clinical trial of traditional Chinese medicine for the treatment of new crown pneumonia on Monday (17th). Meanwhile, the South Asian country is facing a fifth wave of outbreaks triggered by the Opmi kerong variant.

Golden flower clear grains

The conference was jointly organized by the International Institute of Chemistry and Life Sciences (ICCBS) of the University of Karachi and Juxiechang (Beijing) Pharmaceutical Co., Ltd. According to the People's Daily, since April 2020, the University of Karachi and Hunan Medical College have cooperated to carry out clinical research on the effectiveness and safety of Jinhua Qinggan granules in the treatment of new crown pneumonia, relying on the China-Pakistan Traditional Chinese Medicine Cooperation Center jointly established by both sides. Reuters mentioned that the Traditional Chinese medicine "Jinhua Qinggan Granules" produced by China Juxiechang (Beijing) Pharmaceutical Co., Ltd. has been used in China to treat patients with new crown pneumonia.

Professor Iqbal Chaudhry, director of the International Institute of Chemistry and Life Sciences (ICCBS) at the University of Karachi, which conducted the clinical trial in Pakistan, told reporters at the meeting: "Since this chinese medicine is a trial in patients infected with different new coronavirus variants, we expect it to be effective for both Omi kerong and other variants." ”

Raza Shah, the lead researcher in the clinical trial, said the trials, conducted on 300 patients treated at home, were effective in mild to moderate CASES, with an efficiency of about 82.67 percent.

Reuters said the project had previously been approved by Pakistan's Medicines Authority.

Pakistan reported 4,340 confirmed cases of new coronary pneumonia on Monday (17th), which is the highest daily new case recorded in three months. Karachi, the country's largest city, recorded a positive rate (as a percentage of test positives) at the end of last week at 39.39 percent, the highest number to date.

The country's National Command and Operations Centre for COVID-19 Response (NCOC) tweeted Monday that "in the past seven days, confirmed COVID-19 cases in Pakistan have increased by 170% and the death toll has also increased by 62%." ”

According to the official website of Juxiechang (Beijing) Pharmaceutical Co., Ltd., Zhang Boli, an academician of the Chinese Academy of Engineering, once said, "The current research proves that the efficacy of Jinhua Qinggan in the treatment of mild and ordinary new crown pneumonia is exact, which is reflected in the time of fever reduction, the improvement of symptoms and the absorption of inflammation, and the proportion of mild diseases has also decreased." ”

The clinical study conducted by the team of Beijing You'an Hospital found that compared with the Western medical group, the number of nucleic acid to negative days (7.27±3.71 days) in the Jinhua Qinggan granule group was significantly lower than that of the control group (9.80 ± 4.37 days), and the white blood cell recurrence rate (90.2% VS 80.4%) and the lymphocyte recurrence rate (74.5% VS 64.7%) were improved. (Editor: SDY)